EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Emtricitabine And Tenofovir Alafenamide Fumarate, and when can generic versions of Emtricitabine And Tenofovir Alafenamide Fumarate launch?
Emtricitabine And Tenofovir Alafenamide Fumarate is a drug marketed by Apotex and is included in one NDA.
The generic ingredient in EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE is emtricitabine; tenofovir alafenamide fumarate. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the emtricitabine; tenofovir alafenamide fumarate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Emtricitabine And Tenofovir Alafenamide Fumarate
A generic version of EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE was approved as emtricitabine; tenofovir alafenamide fumarate by APOTEX on May 17th, 2024.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE?
- What are the global sales for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE?
- What is Average Wholesale Price for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE?
Summary for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 41 |
| DailyMed Link: | EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE at DailyMed |
Recent Clinical Trials for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Chiang Mai University, Thailand | Phase 3 |
| ANRS, Emerging Infectious Diseases | Phase 3 |
| Assistance Publique - Hôpitaux de Paris, FRANCE | Phase 3 |
See all EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE clinical trials
US Patents and Regulatory Information for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apotex | EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE | emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 214053-001 | May 17, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Apotex | EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE | emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 214053-002 | May 17, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
